Evidence map›Paper›PMID 30783520›Full record

ArticleOncotarget2019

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.

Barbara Adamo, Giuseppina Rosaria Rita Ricciardi, Antonio Ieni, Tindara Franchina, Carmine Fazzari, Maria Vita Sanò, Giuseppe Angelico, Michele Caruso, Giovanni Tuccari, Vincenzo Adamo

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Barbara Adamo *Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.
Giuseppina Rosaria Rita Ricciardi *Medical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.
Antonio IeniDepartment of Human Pathology of Adult and Evolutive Age "Gaetano Barresi", Section of Pathology, University of Messina, AOU Policlinico "G. Martino" Messina, Italy.
Tindara FranchinaMedical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.
Carmine FazzariPathology Unit, Humanitas Center of Oncology, Catania, Italy.
Maria Vita SanòMedical Oncology, Humanitas Catania Oncology Center, Catania, Italy.
Giuseppe AngelicoG. F. Ingrassia Department, Section of Anatomic Pathology, University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy.
Michele CarusoMedical Oncology, Humanitas Catania Oncology Center, Catania, Italy.
Giovanni TuccariDepartment of Human Pathology of Adult and Evolutive Age "Gaetano Barresi", Section of Pathology, University of Messina, AOU Policlinico "G. Martino" Messina, Italy.
Vincenzo AdamoMedical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.20293.].

Identifiers

PMID30783520
PMCPMC6368234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.